Effect of genetic polymorphisms on the pharmacokinetics of gefitinib in healthy Chinese volunteers

References

• Benjamini Y, Hochberg Y. 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B. 57(1):289–300. doi: 10.1111/j.2517-6161.1995.tb02031.x.
   Google Scholar
• Cusatis G, Gregorc V, Li J, Spreafico A, Ingersoll RG, Verweij J, Ludovini V, Villa E, Hidalgo M, Sparreboom A, et al. 2006. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst. 98(23):1739–1742. doi: 10.1093/jnci/djj469.
   PubMedGoogle Scholar
• Fang P, Zheng X, He J, Ge H, Tang P, Cai J, Hu G. 2017. Functional characterization of wild-type and 24 CYP2D6 allelic variants on gefitinib metabolism in vitro. Drug Des Devel Ther. 11:1283–1290. doi: 10.2147/DDDT.S133814.
   PubMed Web of Science ®Google Scholar
• Hsiue EH, Lee JH, Lin CC, Yang JC. 2016. Safety of gefitinib in non-small cell lung cancer treatment. Expert Opin Drug Saf. 15(7):993–1000. doi: 10.1080/14740338.2016.1192605.
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Sato K, Niioka T, Miura H, Ito H, Miura M. 2015. Relationship among gefitinib exposure, polymorphisms of its metabolizing enzymes and transporters, and side effects in Japanese patients with non-small-cell lung cancer. Clin Lung Cancer. 16(4):274–281. doi: 10.1016/j.cllc.2014.12.004.
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Sato K, Niioka T, Takeda M, Okuda Y, Asano M, Ito H, Miura M. 2016. Effects of polymorphisms in CYP2D6 and ABC transporters and side effects induced by gefitinib on the pharmacokinetics of the gefitinib metabolite, O-desmethyl gefitinib. Med Oncol. 33(6):57. doi: 10.1007/s12032-016-0773-5.
   PubMed Web of Science ®Google Scholar
• Kwok WC, Lam DCL, Ip MSM, Tam TCC, Ho JCM. 2022. Association of genetic polymorphisms of CYP3A4 and CYP2D6 with gefitinib-induced toxicities. Anticancer Drugs. 33(10):1139–1144. doi: 10.1097/CAD.0000000000001360.
   PubMed Web of Science ®Google Scholar
• Li J, Zhao M, He P, Hidalgo M, Baker SD. 2007. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res. 13(12):3731–3737. doi: 10.1158/1078-0432.CCR-07-0088.
   PubMed Web of Science ®Google Scholar
• Ma Y, Xin S, Huang M, Yang Y, Zhu C, Zhao H, Zhang Y, Chen L, Zhao Y, Li J, et al. 2017. Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters. Pharmacogenomics J. 17(4):325–330. doi: 10.1038/tpj.2016.31.
   PubMed Web of Science ®Google Scholar
• Ma Y, Xin S, Lin Q, Zhuang W, Zhao Y, Zhu X, Zhao H, Huang M, Xun X, Yang Y, et al. 2019. The analysis of pharmacokinetic and pharmacogenomic impact on gefitinib efficacy in advanced non-small cell lung cancer patients: results from a prospective cohort study. Ann Transl Med. 7(24):806–806. doi: 10.21037/atm.2019.12.60.
   PubMed Web of Science ®Google Scholar
• Mizoguchi K, Nakamura Y, Sano K, Sato S, Ikegami Y, Motoshima K, Takemoto S, Ogawara D, Senju H, Sugasaki N, et al. 2016. Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations. Cancer Chemother Pharmacol. 78(2):377–382. doi: 10.1007/s00280-016-3097-4.
   PubMed Web of Science ®Google Scholar
• Rawluk J, Waller CF. 2018. Gefitinib. Recent Results Cancer Res. 211:235–246. doi: 10.1007/978-3-319-91442-8_16.
   PubMedGoogle Scholar
• Sakamoto S, Sato K, Takita Y, Izumiya Y, Kumagai N, Sudo K, Hasegawa Y, Yokota H, Akamine Y, Okuda Y, et al. 2020. ABCG2 C421A polymorphisms affect exposure of the epidermal growth factor receptor inhibitor gefitinib. Invest New Drugs. 38(6):1687–1695. doi: 10.1007/s10637-020-00946-x.
   PubMed Web of Science ®Google Scholar
• Sausville LN, Williams SM, Pozzi A. 2019. Cytochrome P450 epoxygenases and cancer: a genetic and a molecular perspective. Pharmacol Ther. 196:183–194. doi: 10.1016/j.pharmthera.2018.11.009.
   PubMed Web of Science ®Google Scholar
• Semba Y, Akiyoshi T, Hibino H, Imaoka A, Ohtani H. 2020. Profile of the inhibitory effects of gefitinib on CYP2D6 variants in vitro. Int J Clin Pharmacol Ther. 58(10):539–542. doi: 10.5414/CP203698.
   PubMed Web of Science ®Google Scholar
• Swaisland HC, Cantarini MV, Fuhr R, Holt A. 2006. Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics. Clin Pharmacokinet. 45(6):633–644. doi: 10.2165/00003088-200645060-00006.
   PubMed Web of Science ®Google Scholar
• Tamura M, Kondo M, Horio M, Ando M, Saito H, Yamamoto M, Horio Y, Hasegawa Y. 2012. Genetic polymorphisms of the adenosine triphosphate-binding cassette transporters (ABCG2, ABCB1) and gefitinib toxicity. Nagoya J Med Sci. 74(1-2):133–140.
   PubMed Web of Science ®Google Scholar
• Wan Z, Guo L, Li P, Zhao Z, Xu B, Ren L, Yan Y, Liu H, Zhang Y, Liu L. 2020. Determinants of gefitinib pharmacokinetics in healthy Chinese male subjects: a pharmacogenomic study of cytochrome p450 enzymes and transporters. J Clin Pharm Ther. 45(5):1159–1167. doi: 10.1111/jcpt.13168.
   PubMed Web of Science ®Google Scholar
• Zhang H, Li Q, Zhu X, Wu M, Li C, Li X, Liu C, Shen Z, Ding Y, Hua S. 2018. Association of Variability and Pharmacogenomics With Bioequivalence of Gefitinib in Healthy Male Subjects. Front Pharmacol. 9:849. doi: 10.3389/fphar.2018.00849.
   PubMed Web of Science ®Google Scholar
• Zhao C, Han SY, Li PP. 2017. Pharmacokinetics of gefitinib: roles of drug metabolizing enzymes and transporters. Current Drug Delivery. 14(2):282–288.
   PubMed Web of Science ®Google Scholar